ATAI Life Sciences NV Stock Research

Market Summary

USD1.25+0.02

Delayed

1.63%

ATAI Stock Price

ATAI RSI Chart

ATAI Valuation

Market Cap

207.3M

Price/Earnings (Trailing)

-1.06

Price/Sales (Trailing)

23.35

EV/EBITDA

-0.55

Price/Free Cashflow

-2.18

ATAI Price/Sales (Trailing)

ATAI Profitability

EBT Margin

-676.19%

Return on Equity

-67.81%

Return on Assets

-57.28%

Free Cashflow Yield

-45.89%

ATAI Fundamentals

ATAI Revenue

Revenue Y/Y

-99.65%

Revenue Q/Q

-81.1%

ATAI Earnings

Earnings (TTM)

-196.3M

Earnings Y/Y

-8.76%

Earnings Q/Q

7.46%

Price Action

52 Week Range

1.145.80

(Low)(High)

Last 7 days

-16.9%

Last 30 days

-31.3%

Last 90 days

-59.8%

Trailing 12 Months

-75.1%

ATAI Financial Health

Current Ratio

12.25

Debt/Equity

0.05

Debt/Cashflow

-6.46

ATAI Investor Care

Shares Dilution (1Y)

9.76%

Diluted EPS (TTM)

-1.32

Financials for ATAI Life Sciences

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q3	2022Q2	2021Q4	2021Q3	2021Q2
Revenue	NaN%			20,376,000	40,090,667	59,805,333
Operating Expenses	3.3%	152,821,000	148,001,000	156,181,000	198,013,000	-
S&GA Expenses	-1.0%	80,499,000	81,344,000	92,745,000	138,853,000	-
EBITDA	-4.8%	-144,296,000	-137,679,000	-136,554,000	-	-
EBITDA Margin	-	-6.76	-	-	-	-
Earnings Before Taxes	-4.8%	-144,440,000	-137,780,000	-136,601,000	-179,262,000	-
EBT Margin	-	-6.76	-	-	-	-
Net Income	-1.4%	-196,251,000	-193,522,000	-167,808,000	-165,525,000	-
Net Income Margin	-	-9.50	-	-	-	-
Free Cahsflow	-0.6%	-95,154,000	-94,583,000	-63,419,000	-	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Assets	-1.8%	343	349	384	414	484
Current Assets	-1.9%	317	324	349	375	442
Cash Equivalents	69.4%	143	84.00	124	362	430
Net PPE	140.3%	1.00	0.00	0.00	0.00	0.00
Liabilities	61.4%	47.00	29.00	29.00	28.00	21.00
Current Liabilities	18.0%	26.00	22.00	22.00	21.00	15.00
. Short Term Borrowings	-29.3%	162	228	211	0.00	-
Long Term Debt	Infinity%	15.00	-	-	-	-
Shareholder's Equity	-7.1%	289	312	346	377	453
Retained Earnings	-7.9%	-465	-431	-394	-357	-268
Additional Paid-In Capital	2.1%	762	746	735	725	709
Shares Outstanding	2.6%	166	162	161	161	151
Minority Interest	-20.9%	7.00	8.00	8.00	9.00	10.00

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Cashflow From Operations	0.1%	-94.47	-94.54	-70.71	-63.25	-48.95
Share Based Compensation	-3.8%	44.00	45.00	73.00	63.00	115
Cashflow From Investing	23.6%	-215	-282	-292	-81.28	-36.51
Cashflow From Financing	211.3%	23.00	8.00	379	410	490
Buy Backs	65.0%	2.00	1.00	2.00	1.00	1.00

Risks for ATAI

What is the probability of a big loss on ATAI?

93.5%

Probability that ATAI Life Sciences stock will be more than 20% underwater in next one year

91.3%

Probability that ATAI Life Sciences stock will be more than 30% underwater in next one year.

76.1%

Probability that ATAI Life Sciences stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ATAI drawdown profile look like?

Y-axis is the maximum loss one would have experienced if ATAI Life Sciences was unfortunately bought at previous high price.

Drawdowns

Returns for ATAI

Cumulative Returns on ATAI

Which funds bought or sold ATAI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-02-15	Virtu Financial LLC	sold off	-100	-152,000	-	-%
2023-02-15	Cerity Partners LLC	new	-	3,575,570	3,575,570	0.02%
2023-02-15	JANE STREET GROUP, LLC	reduced	-29.14	-36,224	47,776	-%
2023-02-15	Tejara Capital Ltd	new	-	570,304	570,304	0.33%
2023-02-15	CI Private Wealth, LLC	new	-	39,235	39,235	-%
2023-02-14	Mariner, LLC	new	-	30,000	30,000	-%
2023-02-14	AdvisorShares Investments LLC	added	9.15	-77,638	553,362	0.16%
2023-02-14	TWO SIGMA ADVISERS, LP	added	71.47	316,248	1,151,250	-%
2023-02-14	Cornerstone Planning Group LLC	new	-	780	780	-%
2023-02-14	Engineers Gate Manager LP	new	-	36,219	36,219	-%

Latest Funds Activity

Are funds buying ATAI calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own ATAI

No. of Funds

ATAI Life Sciences News

Schedule 13G FIlings of ATAI Life Sciences

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 01, 2022	galaxy group funding eci u llc	6.7%	10,796,736	SC 13G
Feb 10, 2022	apeiron investment group ltd.	19.7%	32,059,504	SC 13G

ATAI Fair Value

Recent SEC filings of ATAI Life Sciences

View All Filings

Date Filed	Form Type	Document
Mar 16, 2023	4	Insider Trading
Mar 16, 2023	4	Insider Trading
Mar 16, 2023	4	Insider Trading
Mar 16, 2023	4	Insider Trading
Mar 16, 2023	4	Insider Trading
Feb 10, 2023	SC 13G/A	Major Ownership Report

Latest Insider Trading transactions for ATAI

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2022-04-29	Apeiron Investment Group Ltd.	bought	97,801	4.4658	21,900	-
2022-04-28	Apeiron Investment Group Ltd.	bought	154,689	4.4579	34,700	-
2022-04-27	Apeiron Investment Group Ltd.	bought	91,939	4.6427	19,803	-
2022-04-26	Apeiron Investment Group Ltd.	bought	216,628	4.6882	46,207	-
2022-04-25	Apeiron Investment Group Ltd.	bought	42,842	4.781	8,961	-
2022-04-22	Apeiron Investment Group Ltd.	bought	254,962	4.827	52,820	-
2022-04-21	Apeiron Investment Group Ltd.	bought	340,040	4.9505	68,688	-
2022-04-20	Apeiron Investment Group Ltd.	bought	344,514	5.0886	67,703	-
2022-04-19	Apeiron Investment Group Ltd.	bought	334,739	5.125	65,315	-
2022-04-18	Apeiron Investment Group Ltd.	bought	277,656	5.1113	54,322	-

About ATAI Life Sciences

Florian Brand

https://www.atai.life/

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

ATAI Income Statement

2022-09-30

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
License revenue	$ 24	$ 266	$ 195	$ 20,146
Operating expenses:
Research and development	19,028	13,363	52,437	34,974
Acquisition of in-process research and development	0	0	357	8,934
General and administrative	19,419	20,264	54,623	66,868
Total operating expenses	38,447	33,627	107,417	110,776
Loss from operations	(38,423)	(33,361)	(107,222)	(90,630)
Other income (expense), net:
Interest income	145	8	361	80
Change in fair value of contingent consideration liability - related parties	430	469	525	(191)
Change in fair value of derivative liability	0	0	0	41
Change in fair value of warrant liability	0	47	53	87
Change in fair value of securities carried at fair value	344	0	(981)	0
Unrealized loss on other investments held at fair value	0	(70)	0	(5,530)
Loss on conversion of convertible promissory notes	0	0	0	(513)
Gain on consolidation of a variable interest entity	0	0	0	3,543
Foreign exchange gain (loss), net	4,470	6,462	11,515	5,446
Other income (expense), net	(100)	(29)	(112)	(355)
Total other income (expense), net	5,289	6,887	11,361	2,608
Loss before income taxes	(33,134)	(26,474)	(95,861)	(88,022)
Provision for income taxes	(135)	(368)	(227)	(432)
Gain on dilution of equity method investment	0	0	0	16,923
Losses from investments in equity method investees, net of tax	(2,432)	(4,800)	(14,680)	(9,440)
Net loss	(35,701)	(31,642)	(110,768)	(80,971)
Net loss attributable to redeemable noncontrolling interests and noncontrolling interests	(1,814)	(484)	(3,394)	(2,040)
Net loss attributable to ATAI Life Sciences N.V. stockholders	$ (33,887)	$ (31,158)	$ (107,374)	$ (78,931)
Net loss per share attributable to ATAI Life Sciences N.V. stockholders - basic	$ (0.22)	$ (0.21)	$ (0.69)	$ (0.59)
Net loss per share attributable to ATAI Life Sciences N.V. stockholders - diluted	$ (0.22)	$ (0.21)	$ (0.69)	$ (0.59)
Weighted average common shares outstanding attributable to ATAI Life Sciences N.V. Stockholders - basic	156,607,468	151,130,212	154,713,922	134,334,685
Weighted average common shares outstanding attributable to ATAI Life Sciences N.V. stockholders - diluted	156,607,468	151,130,212	154,713,922	134,334,685

ATAI Balance Sheet

2022-09-30

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 142,539	$ 362,266
Securities carried at fair value	161,518	0
Prepaid expenses and other current assets	13,425	11,903
Short term notes receivable	0	913
Total current assets	317,482	375,082
Property and equipment, net	728	149
Equity Method Investments	0	16,131
Other investments	8,498	11,628
Long term notes receivable - related parties	7,151	3,835
Other assets	8,738	7,341
Total assets	342,597	414,166
Current liabilities:
Accounts payable	3,511	6,004
Accrued liabilities	22,142	14,829
Current portion of contingent consideration liability - related parties	0	51
Other current liabilities	260	51
Total current liabilities	25,913	20,935
Non-current portion of contingent consideration liability - related parties	1,908	2,432
Convertible promissory notes - related parties, net of discounts and deferred issuance costs	380	743
Other liabilities	3,695	4,097
Long-term debt, net	14,621	0
Total liabilities	46,517	28,207
Commitments and contingencies (Note 15)
Stockholders' equity:
Common stock, $0.10 par value ($0.12 par value at September 30, 2022 and December 31, 2021, respectively); 750,000,000 shares authorized at September 30, 2022 and December 31, 2021, respectively; 165,875,307 and 160,677,001 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	18,554	18,002
Additional paid-in capital	761,811	725,045
Accumulated other comprehensive loss	(25,788)	(8,336)
Accumulated deficit	(465,178)	(357,803)
Total stockholders' equity attributable to ATAI Life Sciences N.V. stockholders	289,399	376,908
Noncontrolling interests	6,681	9,051
Total stockholders' equity	296,080	385,959
Total liabilities and stockholders' equity	$ 342,597	$ 414,166